Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients - Wikidata - wikimedia - TriplyDB

Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients

Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients

http://www.wikidata.org/entity/Q24617027

about

Oncolytic virus therapy: A new era of cancer treatment at dawn Oncolytic Viruses: Therapeutics With an Identity Crisis Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants Viruses for tumor therapy Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances The GM2 Glycan Serves as a Functional Coreceptor for Serotype 1 Reovirus Viruses as nanomedicine for cancer Sickle Cells Abolish Melanoma Tumorigenesis in Hemoglobin SS Knockin Mice and Augment the Tumoricidal Effect of Oncolytic Virus In Vivo A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy.Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites Endothelial JAM-A promotes reovirus viremia and bloodstream dissemination.The role of pre-existing cross-reactive antibodies in determining the efficacy of vaccination in humans: study protocol for a randomized controlled trial Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients.Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.Mechanisms of reovirus bloodstream dissemination.Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumor Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.Reovirus in cancer therapy: an evidence-based review Genetic determinants of reovirus pathogenesis in a murine model of respiratory infection Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.Reovirus: a targeted therapeutic--progress and potential.Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells Attacking Postoperative Metastases using Perioperative Oncolytic Viruses and Viral Vaccines.The oncolytic virus, pelareorep, as a novel anticancer agent: a review.Applications of coxsackievirus A21 in oncology T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment.Oncolytic virus therapy for cancer.Cell carriers for oncolytic viruses: current challenges and future directions.Nonstructural protein σ1s mediates reovirus-induced cell cycle arrest and apoptosis.Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer.

P2860

Q26739714-1F333FF8-8FB3-4F21-84B5-668E57D991E8 Q26741020-8103E57B-8EC4-4F1A-8CE4-216612B82999 Q26750568-068CA055-FB3D-4653-822C-AF109F923AA1 Q26771799-32A042AA-E643-44C5-91D9-7083785981E8 Q26775030-48CA31EB-EA68-4DF4-9CF7-6C1E431E05F0 Q26775033-3BF9341C-6C76-489D-A236-5026C21A2B04 Q26823826-66462582-8978-4DB3-95E6-0C1AD01B3B2E Q26863779-D4A6FEF1-6909-42F7-9719-5A6375CB4FF3 Q27675479-1729E4FC-E7E1-4DE7-8AED-E51486C00260 Q27690636-70EE23BF-0984-4149-A417-2F5A09221805 Q28596621-74D072B6-EC91-4249-854C-5D4862CEE6EB Q33418048-54D4CDC9-3529-4163-964A-9805B3692D53 Q33551626-BE20DA67-212A-47BD-9540-C141C5C14C05 Q34127857-8C151EEF-523B-4E7F-867D-D615A2A00243 Q35061974-1773EB87-E8A5-44B1-9DB1-6A8D8E81DD6B Q35152799-A003EAE1-33B7-4514-95F1-8B79C9E0EC87 Q35496004-365FD86B-3B3E-4D59-96F2-9130E6C2919D Q35522211-AC97805F-C1B3-44A5-8D05-84676481E147 Q35596563-B7A22390-E46D-48F8-9F3D-C4D2F5201477 Q35812675-2561B967-027B-41B3-9429-11B7D92C1774 Q36155563-424CB573-9D3F-4609-A67B-17A8B05D9A7A Q36390114-A012D20E-BE6C-4DC9-9AE3-6A50BA73894C Q36766032-CAA5378F-1647-4F7A-82E9-41755F2EB199 Q37031909-E8BEA85F-AF06-44D8-A03E-B1AE612C79E5 Q37123318-9C0BC0EC-9A6E-41D7-8338-BDAE57D582AB Q37267785-C2E4AD87-DEE3-42C8-B020-DB65DD011A44 Q37347236-D27572BD-7320-4DED-A091-6E414B9AAE6D Q37360608-8A8F9D0C-3CCC-4564-8B6C-A2F55592DA45 Q37477574-34D52EAB-6014-4771-8B3D-85199E2F5F59 Q38243811-FC490815-841B-4238-8E62-FA792350A0F2 Q38360781-27D56ACD-3F15-4DE8-BD80-249D6EC65B03 Q38564325-F851CFDF-F7DE-4053-B40A-083D328EC530 Q38648630-1E9A855C-DA1E-4B98-9801-CD86D869B4C1 Q38799217-B5072FF9-4BB1-4361-AFDB-0A84F242803B Q38878906-9705DB93-48D5-416C-99AC-192495D4DCC7 Q38912287-3301B84F-1213-4BD8-904F-49988FD895D2 Q38924529-1C5828A8-E2DD-4024-B4CF-929395223146 Q38924531-0E6A602F-9BA8-4E9C-BE19-189BFA93554C Q39091807-6F49A235-A862-47EC-BE76-3C2267429C05 Q40429665-29314446-B742-40BE-B238-429A855E9B81

P2860

Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients

http://www.wikidata.org/entity/Q24617027

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Cell carriage, delivery, and s ...... tic virus in tumor in patients

@ast

Cell carriage, delivery, and s ...... tic virus in tumor in patients

@en

Cell carriage, delivery, and s ...... tic virus in tumor in patients

@en-gb

Cell carriage, delivery, and s ...... tic virus in tumor in patients

@nl

type

label

Cell carriage, delivery, and s ...... tic virus in tumor in patients

@ast

Cell carriage, delivery, and s ...... tic virus in tumor in patients

@en

Cell carriage, delivery, and s ...... tic virus in tumor in patients

@en-gb

Cell carriage, delivery, and s ...... tic virus in tumor in patients

@nl

prefLabel

Cell carriage, delivery, and s ...... tic virus in tumor in patients

@ast

Cell carriage, delivery, and s ...... tic virus in tumor in patients

@en

Cell carriage, delivery, and s ...... tic virus in tumor in patients

@en-gb

Cell carriage, delivery, and s ...... tic virus in tumor in patients

@nl

P1433

Q24617027-A92A66E1-B2AE-4333-B0D5-0DEA5096403F

P1476

Q24617027-B9784141-CC41-47A7-BB01-D50DABBC5A63

P2093

Q24617027-2E1CA7FD-AFC2-4E00-8122-45515C484C3D

Q24617027-3E088E06-FE78-4128-859A-1B3787D556FA

Q24617027-4C5A83D0-6A92-4AC5-982E-5F6ADF11D085

Q24617027-4DF8A551-63F2-4B18-9A42-4FA98FBC8741

Q24617027-5764DE7F-4700-4524-A018-442EDF283143

Q24617027-7D7D2E98-B311-42BD-9752-B2870A9DEF96

Q24617027-7EBE6D09-3039-43C0-9E40-8F743AFF1CBC

Q24617027-80BE569B-EE6E-4E7B-8E6B-17D3042A75E7

Q24617027-85B862BA-902F-46A0-829E-E186A586D5D0

Q24617027-87DDC7BE-6735-4604-B5A5-404B2FC066C5

P2860

Q24617027-0088B9F7-5497-43F9-A02E-5774C5557EEF

Q24617027-07AB6712-D144-400E-B5E5-DE1D58273574

Q24617027-0AEB4F7F-8737-4D23-B174-4D2AB5961D20

Q24617027-0B202C49-52BE-44C7-BDE9-F19BA61989CF

Q24617027-23BB266B-65EB-45A0-B116-771D10DBF341

Q24617027-2439209D-8C49-4AF1-9643-A6D47038E851

Q24617027-24E3DDA6-4C36-4AB7-98E7-4B7A1C5F3011

Q24617027-2F258D55-C61C-47D5-BF89-5135C33700D0

Q24617027-3B844BCF-C429-41AE-8E0F-3ACB8EF699AD

Q24617027-3F7105F5-8D8E-40E1-BFF4-56360FC51D6A

P304

Q24617027-FD1329A5-4C38-4D1C-AF22-F1C2153B77D9

P31

Q24617027-730054B6-C4AC-42B2-BBD2-4EEDB7674605

P3181

Q24617027-C03C6CEF-1443-47D2-8416-34D36301A320

P356

Q24617027-45CECC1A-1059-47E7-BC2B-3F4D223A0308

P407

Q24617027-EF757A7B-0BBD-4E7F-B108-01593DD187F4

P433

Q24617027-A017BCC4-D626-4856-AC3C-F59A56B20CF1

P478

Q24617027-093DDC88-B48D-404E-979C-D8791EAB0A8C

P50

Q24617027-7578272D-9B9A-4B11-9CAD-64EC5BF0CA21

Q24617027-C3FD5804-535F-4CE1-868C-FBAA17E887FF

Q24617027-E73A01AB-887E-48DD-AD7C-A7BB277C7C53

Q24617027-F945783F-FCF4-4D59-8F14-1BBF818B5C87

P577

Q24617027-DB2791F1-2A23-4A92-AF0F-23EECAF454FF

P698

Q24617027-6D6B3A09-DD62-4501-AE2F-BD9AAAF0E730

P921

Q24617027-22338C71-8D9B-4393-B47A-92BE294F52B3

Q24617027-22DA928F-C9CE-46F2-9954-CBCDB79E0051

Q24617027-36187F27-428F-4392-B74D-1AAC98CBF268

P932

Q24617027-7F4975B7-83A2-46BC-9721-1A648C2AB807

P3181

P356

SCITRANSLMED.3003578

P1433

Science Translational Medicine

P1476

Cell carriage, delivery, and s ...... tic virus in tumor in patients

@en

P2093

Ailsa Rose

http://www.w3.org/2001/XMLSchema#string

Alan A Melcher

http://www.w3.org/2001/XMLSchema#string

Alison Merrick

http://www.w3.org/2001/XMLSchema#string

Amer Aldouri

http://www.w3.org/2001/XMLSchema#string

David A Anthoney

http://www.w3.org/2001/XMLSchema#string

Deborah Beirne

http://www.w3.org/2001/XMLSchema#string

Emma J West

http://www.w3.org/2001/XMLSchema#string

Gerard J Nuovo

http://www.w3.org/2001/XMLSchema#string

Hardev Pandha

http://www.w3.org/2001/XMLSchema#string

Joan Kyula

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.

Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver.

A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer.

Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy.

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.

Reovirus: Rationale and clinical trial update.

Oncolytic viruses: a novel form of immunotherapy.

Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.

P304

138ra77

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3441583

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCITRANSLMED.3003578

http://www.w3.org/2001/XMLSchema#string

P407

P433

138

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Giles J. Toogood

Oliver Donnelly

P577

2012-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22700953

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

3893925

http://www.w3.org/2001/XMLSchema#string